HIF1A and Sepsis: This effect may be linked to the effect of regorafenib in inhibiting HIF-1α, a known inducer of VEGF release, which is activated by toll-like receptors during sepsis and plays a key role in the reprogramming of innate immune cells, thus potentially reducing VEGF levels and mitigating acute lung injury [21].